The success of CDK4/6 inhibitors in the treatment of patients with breast cancer has sparked the creation of novel cell cycle inhibitors that target various stages of the cell cycle, resulting in the emergence of various types of inhibitors with diverse anti-tumorigenic mechanisms (Chiappa et al., 2022; Ploumaki et al., 2024). Here, CDK4 is linked to breast cancer.